Published By: Syndicate Market Research
Adalimumab Market - Global Industry Analysis, Size,
Share, Growth, Trends and Forecast 2014 - 2020
3422 SW 15 Street, Suit #8138,
Florida 33442, USA
Toll Free: 1-855-465-4651
Adalimumab is a biologic TNF inhibiting anti-inflammatory medication which is a patented medicine
of Abbott Biotechnology Ltd. Jochen G. Salfeld et al invented the product and trade names for the
product are Exemptia and Humira. Humira stands for "human monoclonal antibody in rheumatoid
arthritis". Humira targets and acts as building block for TNF-alpha production, and lowering
inflammation. TNF blockers with HUMIRA, has adverse affects on the immune system which is a
serious side effect of this medicine. Adalimumab is prescribed for Crohn’s disease, Rheumatoid
arthritis, ulcerative colitis and psoriasis disorders. PsA leads to excess production of definite proteins,
and people with PsA, TNF causes swelling in joints.
Increasing number of female populace is becoming susceptible to arthritis due to loss of body
calcium. Rising occurrence of arthritis is a main driver for the growth of the adalimumab market.
Enhanced analysis rate along with the introduction of proficient biologic drugs are also some of the
major factors to support the market growth. Additional, growing deskbound routine is boosting the
prevalence of arthritis commonness. On the other side, high price and low openness are the foremost
factor restricting the escalation of the global adalimumab market.
The report covers forecast and analysis for the adalimumab market on a global and regional level.
The study provides significant data of 2014 along with estimated from 2014 to 2020 based on
revenue (USD Million). The report also offers detailed competitive landscape of the global...